Bergur V. Stefánsson

9.6k total citations · 3 hit papers
57 papers, 5.4k citations indexed

About

Bergur V. Stefánsson is a scholar working on Endocrinology, Diabetes and Metabolism, Nephrology and Surgery. According to data from OpenAlex, Bergur V. Stefánsson has authored 57 papers receiving a total of 5.4k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Endocrinology, Diabetes and Metabolism, 26 papers in Nephrology and 19 papers in Surgery. Recurrent topics in Bergur V. Stefánsson's work include Diabetes Treatment and Management (40 papers), Pancreatic function and diabetes (17 papers) and Chronic Kidney Disease and Diabetes (16 papers). Bergur V. Stefánsson is often cited by papers focused on Diabetes Treatment and Management (40 papers), Pancreatic function and diabetes (17 papers) and Chronic Kidney Disease and Diabetes (16 papers). Bergur V. Stefánsson collaborates with scholars based in Sweden, United States and Netherlands. Bergur V. Stefánsson's co-authors include Hiddo J.L. Heerspink, C. David Sjöström, David C. Wheeler, Peter Rossing, Glenn M. Chertow, Ricardo Correa‐Rotter, John J.V. McMurray, Tom Greene, Fan Fan Hou and Johannes F.E. Mann and has published in prestigious journals such as New England Journal of Medicine, Circulation and SHILAP Revista de lepidopterología.

In The Last Decade

Bergur V. Stefánsson

57 papers receiving 5.3k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Dapagliflozin in Patients with Chronic Kidney Disease

2020 3.0k citations Hiddo J.L. Heerspink, Bergur V. Stefánsson et al. profile →
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

2020 355 citations David C. Wheeler, Bergur V. Stefánsson et al. The Lancet Diabetes & Endocrinology profile →
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy

2021 237 citations David C. Wheeler, Robert D. Toto et al. Kidney International profile →

Peers

Countries citing papers authored by Bergur V. Stefánsson

Since Specialization

Citations

This map shows the geographic impact of Bergur V. Stefánsson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bergur V. Stefánsson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bergur V. Stefánsson more than expected).

Fields of papers citing papers by Bergur V. Stefánsson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bergur V. Stefánsson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bergur V. Stefánsson. The network helps show where Bergur V. Stefánsson may publish in the future.

Co-authorship network of co-authors of Bergur V. Stefánsson

This figure shows the co-authorship network connecting the top 25 collaborators of Bergur V. Stefánsson. A scholar is included among the top collaborators of Bergur V. Stefánsson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bergur V. Stefánsson. Bergur V. Stefánsson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial 2022 ·Diabetologia ·(unknown), Priya Vart, David Z.I. Cherney, Glenn M. Chertow, Niels Jongs, Anna Maria Langkilde, Johannes F.E. Mann, Ofri Mosenzon, John J.V. McMurray, Peter Rossing, Ricardo Correa‐Rotter, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink	35
2	Loop and thiazide diuretic use and risk of chronic kidney disease progression: a multicentre observational cohort study 2022 ·BMJ Open ·Jesse K. Fitzpatrick, Jingrong Yang, Andrew P. Ambrosy, Claudia Cabrera, Bergur V. Stefánsson, Peter J. Greasley, Jignesh M. Patel, Thida C. Tan, Alan S. Go	9
3	Effects of Dapagliflozin in Stage 4 Chronic Kidney Disease 2021 ·UCL Discovery (University College London) ·Glenn M. Chertow, Priya Vart, Niels Jongs, Robert D. Toto, José Luis Górriz, Fan Fan Hou, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Anna Maria Langkilde, David C. Wheeler, Hiddo J.L. Heerspink, (unknown)	80
4	Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure 2021 ·JACC Heart Failure ·John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa‐Rotter, Glenn M. Chertow, Fan Fan Hou, Peter Rossing, C. David Sjöström, Scott D. Solomon, Robert D. Toto, Anna Maria Langkilde, Hiddo J.L. Heerspink	62
5	Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial 2021 ·The Lancet Diabetes & Endocrinology ·Niels Jongs, Tom Greene, Glenn M. Chertow, John J.V. McMurray, Anna Maria Langkilde, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Bergur V. Stefánsson, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink	126
6	Treatments for Chronic Kidney Disease: A Systematic Literature Review of Randomized Controlled Trials 2021 ·Advances in Therapy ·Juan José García Sánchez, Juliette C. Thompson, David A. Scott, Rachel Evans, (unknown), Elisabeth Sörstadius, Glen James, Stephen Nolan, Eric Wittbrodt, Alyshah Abdul Sultan, Bergur V. Stefánsson, Dan Jackson, Keith R. Abrams	22
7	A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy breakdown → 2021 ·Kidney International ·David C. Wheeler, Robert D. Toto, Bergur V. Stefánsson, Niels Jongs, Glenn M. Chertow, Tom Greene, Fan Fan Hou, John J.V. McMurray, Roberto Pecoits‐Filho, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Kausik Umanath, Anna Maria Langkilde, Hiddo J.L. Heerspink	237
8	The Kidney Protective Effects of the Sodium–Glucose Cotransporter-2 Inhibitor, Dapagliflozin, Are Present in Patients With CKD Treated With Mineralocorticoid Receptor Antagonists 2021 ·Kidney International Reports ·Michele Provenzano, Niels Jongs, Priya Vart, Bergur V. Stefánsson, Glenn M. Chertow, Anna Maria Langkilde, John J.V. McMurray, Ricardo Correa‐Rotter, Peter Rossing, C. David Sjöström, Robert D. Toto, David C. Wheeler, Hiddo J.L. Heerspink	50
9	Correction of anemia by dapagliflozin in patients with type 2 diabetes 2020 ·Journal of Diabetes and its Complications ·Bergur V. Stefánsson, Hiddo J.L. Heerspink, David C. Wheeler, C. David Sjöström, Peter J. Greasley, Peter Sartipy, Valerie A. Cain, Ricardo Correa‐Rotter	32
10	Effect of Dapagliflozin on Clinical Outcomes in Patients With Chronic Kidney Disease, With and Without Cardiovascular Disease 2020 ·Circulation ·John J.V. McMurray, David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, Douwe Postmus, Ricardo Correa‐Rotter, Glenn M. Chertow, Tom Greene, Claes Held, Fan Fan Hou, Johannes F.E. Mann, Peter Rossing, C. David Sjöström, (unknown), Anna Maria Langkilde, Hiddo J.L. Heerspink	100
11	Correction of hypomagnesemia by dapagliflozin in patients with type 2 diabetes: A post hoc analysis of 10 randomized, placebo-controlled trials 2019 ·Journal of Diabetes and its Complications ·Robert D. Toto, Ronald Goldenberg, Glenn M. Chertow, Valerie A. Cain, Bergur V. Stefánsson, C. David Sjöström, Peter Sartipy	33
12	Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus 2018 ·BMC Nephrology ·(unknown), Alan S. Go, Jingrong Yang, Thida C. Tan, Claudia Cabrera, Bergur V. Stefánsson, Peter J. Greasley, Juan D. Ordoñez	74
13	Effects of Tenapanor on Cytochrome P450‐Mediated Drug‐Drug Interactions 2017 ·Clinical Pharmacology in Drug Development ·Susanne Johansson, David P. Rosenbaum, (unknown), (unknown), Mikael Knutsson, Bergur V. Stefánsson, Marie Elebring	10
14	Tenapanor administration and the activity of the H⁺‐coupled transporter PepT1 in healthy volunteers 2017 ·British Journal of Clinical Pharmacology ·Susanne Johansson, David P. Rosenbaum, Johan Palm, Bergur V. Stefánsson, Mikael Knutsson, Eleanor Lisbon, Constanze Hilgendorf	10
15	A retrospective, longitudinal study estimating the association between interdialytic weight gain and cardiovascular events and death in hemodialysis patients 2015 ·BMC Nephrology ·Claudia Cabrera, Steven M. Brunelli, David P. Rosenbaum, Emmanuel A. Anum, Karthik Ramakrishnan, Donna E. Jensen, Nils‐Olov Stålhammar, Bergur V. Stefánsson	46
16	Hemodiafiltration Improves Plasma 25-Hepcidin Levels: A Prospective, Randomized, Blinded, Cross-Over Study Comparing Hemodialysis and Hemodiafiltration 2012 ·SHILAP Revista de lepidopterología ·Bergur V. Stefánsson, (unknown), Ulf Nilsson, Börje Haraldsson	20
17	Dosing of Erythropoiesis-Stimulating Agents Can Be Reduced by a New Administration Regimen 2011 ·PubMed ·Bergur V. Stefánsson, Börje Haraldsson, Ulf Nilsson	1
18	Acute Oxidative Stress following Intravenous Iron Injection in Patients on Chronic Hemodialysis: A Comparison of Iron-Sucrose and Iron-Dextran 2010 ·Nephron Clinical Practice ·Bergur V. Stefánsson, Börje Haraldsson, Ulf Nilsson	23
19	A new method for monitoring nitric oxide production using Teflon membrane microdialysis 2005 ·Free Radical Biology and Medicine ·Bergur V. Stefánsson, (unknown), Börje Haraldsson, Ulf Nilsson	9
20	Angiotensin-Converting Enzyme Gene I/D Polymorphism in Malignant Hypertension 2000 ·Blood Pressure ·Bergur V. Stefánsson	18

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact